The U.K.'s National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on Paige's Paige Prostate artificial intelligence (AI) software.
MIBs are intended to support the U.K.'s National Health Service (NHS) facilities when they are considering the use of new medical devices, Paige said. This MIB is the first for a digital pathology product, according to the firm.
Paige Prostate helps pathologists detect, grade, and measure prostate tumors in biopsies taken from patients at risk of the disease, the company said. The MIB included a review of 3,444 prostate needle biopsies and found that Paige Prostate shows promise as an effective tool for detecting prostate cancer.
Paige Prostate is U.S. Food and Drug Administration (FDA) cleared and CE-Marked, according to Paige.
